NAYA
RAi
NAYARAi™

Resources

22 07 2026CDSCOPDF

Clarification regarding submission of applications under Rule 4 of the Drugs and Cosmetics (Compounding of Offences) Rules, 2025.

+
22 07 2026WHOPDF

Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredients

+
22 07 2026MHRAPDF

MHRA approves world's first lower-carbon beclometasone inhalers for patients with asthma

+
22 07 2026MHRAPDF

Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

+
22 07 2026MHRAPDF

MHRA: policy for handling corporate conflicts of interest

+
22 07 2026FDAPDF

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notifications Submission

+
22 07 2026FDAPDF

Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

+
21 07 2026MHRAPDF

Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35

+
21 07 2026FDAPDF

Expedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Period

+
20 07 2026CDSCOPDF

Constitution of Consultancy Committee of Key Stakeholders for Advice on Suo-Motu Disclosure under Section 4 of the RTI Act, 2005 in CDSCO

+
20 07 2026CDSCOPDF

Sale of In-Vitro Fertilization media, reagents and related consumables used in Assisted Reproductive Technology procedures

+
20 07 2026CDSCOPDF

Submission of Post Approval Changes Applications of Registration Certificate and Import Licence of Human Vaccines and Anti-sera through SUGAM Portal

+
20 07 2026CDSCOPDF

Regulation of Formulation intermediates such as Directly Compressible granules, Taste masked granules, Modified release granules / Pellets

+
20 07 2026CDSCOPDF

Inviting comments on consideration of the proposal regarding Issue of use of brand name extensions by the pharmaceutical firms

+
20 07 2026MHRAPDF

Orphan registered medicinal products

+
20 07 2026MHRAPDF

Medical devices given exceptional use authorisations

+
20 07 2026MHRAPDF

Custom-made medical devices in Great Britain

+
20 07 2026MHRAPDF

Medical devices: legal requirements for specific medical products

+
20 07 2026MHRAPDF

Register medical devices to place on the market

+
20 07 2026EMAPDF

EMA fast tracks review of a medicine for metastatic pancreatic cancer

+